P.316 The use of cannabidiol in treating psychiatric disorder: a systematic review
- 25 February 2021
- journal article
- conference paper
- Published by Elsevier BV in European Neuropsychopharmacology
- Vol. 44, S50
- https://doi.org/10.1016/j.euroneuro.2021.01.077
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Cannabidiol Adverse Effects and ToxicityCurrent Neuropharmacology, 2019
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled TrialAmerican Journal of Psychiatry, 2018
- Endocannabinoids in nervous system health and disease: the big picture in a nutshellPhilosophical Transactions B, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012